Denali Therapeutics (DNLI) Cash from Financing Activities (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Cash from Financing Activities data on file, last reported at $219.0 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $219.0 million, up 5922.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $412.0 million (up 2187.98% YoY), and the FY2025 annual result was $189.2 million, down 60.93% from the prior year.
• Cash from Financing Activities improved to $219.0 million in Q1 2026 per DNLI's latest filing, from $192.1 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $500.3 million in Q1 2024 and troughed at -$18.6 million in Q3 2024.
• A 5-year average of $71.8 million and a median of $4.4 million in 2022 frame the typical range for Cash from Financing Activities.
• On a YoY basis, Cash from Financing Activities climbed as much as 31089.21% in 2024 and fell as far as 844.74% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at $299.7 million in 2022, then tumbled by 98.43% to $4.7 million in 2023, then sank by 188.59% to -$4.2 million in 2024, then jumped by 4709.72% to $192.1 million in 2025, then increased by 14.01% to $219.0 million in 2026.
• Business Quant data shows DNLI's Cash from Financing Activities at $219.0 million in Q1 2026, $192.1 million in Q4 2025, and -$778000.0 in Q3 2025.